within Pharmacolibrary.Drugs.C_CardiovascularSystem.C03D_AldosteroneAntagonistsAndOtherPotassiumSparingAg.C03DB02_Triamterene;

model Triamterene
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.52,
    Cl = 3.694444444444444e-05,
    adminDuration = 600,
    adminMass = 100 / 1000000,
    adminCount = 1,
    Vd = 0.0011,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.00265,
    Tlag = 900);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Triamterene</td></tr><tr><td>ATC code:</td><td>C03DB02</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>100</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.1</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.9</td><td>L/hr/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Triamterene is a potassium-sparing diuretic used in the management of edema and hypertension, often in combination with other diuretics such as hydrochlorothiazide. It acts on the distal renal tubules to inhibit sodium reabsorption while conserving potassium. It is approved and widely used clinically.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.C.C03DB02 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Triamterene;
